Abstract 2485
Background
Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality. This study focused on identification of RNA-Seqexpressionsignature for prognosis prediction of Uterine Sarcoma.
Methods
We obtained RNA-Seqexpression profiles from The Cancer Genome Atlas (TCGA) database and differential expressed genes (DEGs) were identified between US tissues and normal tissues. Univariate Cox proportional hazards regression analysis was performed to identify Prognosis associated DEGscorrelated with survival of US patients.The RNA-Seqbased prognostic signature was identified by least absolute shrinkage and selection operator (LASSO) Cox model. The cohort was randomly divided into training and testing groups. Thebiological pathway and processof putative RNA targets was also analyzed by bioinformatics.
Results
This study identified a RNA-Seq signature based on 11 genes, AP000320.1, HNRNPA1P33, RPL21P10, AC067773.1, AC011933.3, STX19, AC091133.4, HIST1H3A, AC004988.1, AL356585.1 and HNRNPA3P1. In the training group, the median OS in the high-risk and low-risk groups were 13.7 vs 88.1 months (HR, 0.204, 95% CI, 0.08589 - 0.4846; P < 0.0001), respectively. In the testing group, the median OS in the high-risk and low-risk groups were 11.9 vs 67.2 months (HR, 0.04315, 95% CI, 0.004845 - 0.3842; P < 0.0001) respectively. Genes in the model were put into gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes signaling pathways analysis, which suggested that these genes might contribute to cancer-associated processes such as the nuclear nucleosome and DNA packaging complex.
Conclusions
This 11-genebased prognostic signature may improve prognosis prediction of US.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Linguistic correction
Resources from the same session
5134 - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials).
Presenter: OLIVIER COLOMBAN
Session: Poster Display session 2
Resources:
Abstract
4410 - Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients (pts) with ovarian cancer
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
5077 - Response to Pegylated Liposomal Doxorubicin (PLD) and Weekly Paclitaxel (wpac) in Platinum Resistant (PR) Ovarian Cancer (OC) by BRCA mutation status
Presenter: Louise Bremer
Session: Poster Display session 2
Resources:
Abstract
3483 - Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Presenter: Bradley Monk
Session: Poster Display session 2
Resources:
Abstract
5423 - OCTAVE - A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
Presenter: Iain McNeish
Session: Poster Display session 2
Resources:
Abstract
1385 - Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)
Presenter: Natalie Ngoi
Session: Poster Display session 2
Resources:
Abstract
2090 - Phase 1b/2a study assessing the safety and efficacy of adding AL3818 (Anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
Presenter: David Miller
Session: Poster Display session 2
Resources:
Abstract
1960 - Phase I Study of Intraperitoneal TRX-E-002-1 in Subjects with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Three-month Follow-up Results of the Dose Escalation Phase
Presenter: Jermaine Coward
Session: Poster Display session 2
Resources:
Abstract
4288 - Hybrid capture-based genomic profiling of circulating tumor DNA (ctDNA) from patients with ovarian cancer
Presenter: Mi Yang
Session: Poster Display session 2
Resources:
Abstract
3433 - Tumor Microvessel Density for predicting Nintedanib activity: data from the randomized CHIVA trial (a GINECO study)
Presenter: Maud Villemin
Session: Poster Display session 2
Resources:
Abstract